# Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Source: https://onco.cc/trials/nct04959903/  
OnCo record `nct04959903` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Allogeneic T cell progenitors, cultured ex-vivo in advanced solid tumours, run by Smart Immune SAS, now recruiting.

## Summary

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT is a phase 1/2 interventional study registered as NCT04959903 by Smart Immune SAS, with 36 participants planned, started 2022-03-31 and due to reach its primary completion in 2025-08. Interventions recorded: Allogeneic T cell progenitors, cultured ex-vivo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04959903
- Phase: 1/2
- Setting: A Phase I/II Study Evaluating the Safety and the Efficacy of SMART101 Injection to Accelerate Immune Reconstitution After T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Adult Patients With Hematological Malignancies
- Sponsor: Smart Immune SAS
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT04959903: https://clinicaltrials.gov/study/NCT04959903

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct04959903.json